Dehydrocorydaline

Dehydrocorydaline (0-200 μM) treatment significantly inhibits the growth of MCF-7 cells in a dose-dependent manner. The cell viability is decreased by approximate 40% after 24 h of 200 μM Dehydrocorydaline.
Dehydrocorydaline (0-200 μM) dose-dependently increases Bax protein expression and decreases Bcl-2 protein expression.
Dehydrocorydaline (0-200 μM) induces activation of caspase-7,-8 and the cleavage of PARP without affecting caspase-9.

Dehydrocorydaline manifests a low acute toxicity with an LD ₅₀ of about 277.5±19.0 mg/kg body weight in mice following oral administration and 21.1±1.4 mg/kg for intraperitoneal injection. < /p>